Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICHOLAS PATRICK MCANDREW

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093074106
CMS profile
906526
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$12,939.92

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $9,848.78 9
Novartis Pharmaceuticals Corporation $3,091.14 3

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICHOLAS PATRICK MCANDREW

NPI 1093074106 · CMS profile ID 906526

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093074106?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093074106?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093074106?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1093074106?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $12,939.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $2,910.0007/15/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739474919 CMS
Novartis Pharmaceuticals Corporation $470.0005/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726010490 CMS
Daiichi Sankyo Inc. $5,820.0002/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739473325 CMS
Daiichi Sankyo Inc. $210.9602/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739473757 CMS
Novartis Pharmaceuticals Corporation $2,500.0201/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726010483 CMS
Novartis Pharmaceuticals Corporation $121.1201/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726010485 CMS
Daiichi Sankyo Inc. $25.0001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739472799 CMS
Daiichi Sankyo Inc. $12.0001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739472801 CMS
Daiichi Sankyo Inc. $35.0001/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739472803 CMS
Daiichi Sankyo Inc. $656.8001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739472795 CMS
Daiichi Sankyo Inc. $136.4001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739472797 CMS
Daiichi Sankyo Inc. $42.6201/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739510657 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,170.23 5
PY2020 $12,939.92 12
PY2021 $2,820.00 2
PY2022 $8,355.00 3
PY2023 $854.83 4
PY2024 $4,405.87 15
PY2025 $9,621.75 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $872.20 1
PY2025 Principal investigator $596,816.77 153
PY2024 Recipient $1,633.83 1
PY2024 Principal investigator $3,352,829.60 63
PY2023 Recipient $1,409.82 1
PY2023 Principal investigator $2,151,571.63 67
PY2022 Principal investigator $2,868,775.41 36
PY2021 Principal investigator $3,830,116.22 25
PY2020 Principal investigator $6,585,760.41 40
PY2019 Principal investigator $3,438,563.63 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $14,302.00 12/30/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932044
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,411.36 12/19/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab No dispute reported 06/30/2026 1089696331
Principal investigator 1 PFIZER INC. $867.00 12/16/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1130900190
Principal investigator 1 Daiichi Sankyo Inc. $76,858.20 12/13/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U301 No dispute reported 06/30/2026 1145040562
Principal investigator 1 PFIZER INC. $138,829.21 12/09/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER No dispute reported 06/30/2026 1130914687
Principal investigator 1 PFIZER INC. $17,334.00 12/09/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932464
Principal investigator 1 Eli Lilly and Company $20,020.50 11/14/2024 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION No dispute reported 06/30/2026 1137351834
Principal investigator 1 Daiichi Sankyo Inc. $397,580.10 11/07/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040258
Principal investigator 1 Daiichi Sankyo Inc. $390,183.35 10/31/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040256
Principal investigator 1 PFIZER INC. $41,773.58 10/09/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER No dispute reported 06/30/2026 1130933007
Principal investigator 1 PFIZER INC. $15,027.00 09/26/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933003
Principal investigator 1 PFIZER INC. $867.00 09/26/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130933014
Principal investigator 1 PFIZER INC. $128,150.04 09/12/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER No dispute reported 06/30/2026 1130932926
Principal investigator 1 PFIZER INC. $600.00 09/11/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130930243
Principal investigator 1 Novartis Pharmaceuticals Corporation $349.00 08/19/2024 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690129
Principal investigator 1 PFIZER INC. $10,621.66 08/13/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130929302
Principal investigator 1 PFIZER INC. $21,358.34 08/13/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130930251
Principal investigator 1 PFIZER INC. $21,358.34 08/09/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130933022
Principal investigator 1 PFIZER INC. $5,481.00 08/07/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130933034
Principal investigator 1 Daiichi Sankyo Inc. $390,183.35 07/24/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040254
Principal investigator 1 PFIZER INC. $20,764.00 07/24/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130928956
Principal investigator 1 PFIZER INC. $4,135.00 07/24/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130928960
Principal investigator 1 PFIZER INC. $128,150.04 07/02/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER No dispute reported 06/30/2026 1130933010
Principal investigator 1 PFIZER INC. $11,340.00 06/20/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932938
Principal investigator 1 Daiichi Sankyo Inc. $4,543.56 06/19/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040252
Principal investigator 1 PFIZER INC. $21,243.32 06/18/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932896
Principal investigator 1 Veru Inc. $110,981.00 06/18/2024 Non-covered Recipient Entity
The Regents of the University of California on behalf of its Los Angeles campus
VERU_V3002401_4063_01 No dispute reported 06/30/2026 1150702450
Principal investigator 1 PFIZER INC. $41,773.58 06/12/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER No dispute reported 06/30/2026 1130929628
Principal investigator 1 Novartis Pharmaceuticals Corporation $157,202.64 06/11/2024 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab No dispute reported 06/30/2026 1089690415
Principal investigator 1 Daiichi Sankyo Inc. $397,580.10 05/30/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040250
Principal investigator 1 PFIZER INC. $1,156.00 05/22/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130933030
Principal investigator 1 PFIZER INC. $800.00 05/15/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130929901
Principal investigator 1 PFIZER INC. $9,079.00 05/15/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932627
Principal investigator 1 PFIZER INC. $1,156.00 04/24/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130929632
Principal investigator 1 PFIZER INC. $3,764.00 04/10/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130930247
Principal investigator 1 PFIZER INC. $24,287.00 03/27/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130929890
Principal investigator 1 PFIZER INC. $8,755.00 03/20/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130930382
Principal investigator 1 PFIZER INC. $4,652.00 03/13/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130930059
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,673.00 02/29/2024 Non-covered Recipient Entity
UCLA HEM ONCOLOGY LAGUNA HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690161
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,200.00 02/29/2024 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY ENCINO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690199
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,675.00 02/29/2024 Non-covered Recipient Entity
UCLA BURBANK
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690379
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,870.00 02/29/2024 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690421
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,531.00 02/29/2024 Non-covered Recipient Entity
UCLA HEALTH PASADENA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089690451
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,055.00 02/29/2024 Non-covered Recipient Entity
UCLA VALENCIA
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089691045
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,342.00 02/29/2024 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089697479
Principal investigator 1 Novartis Pharmaceuticals Corporation $113,254.03 02/14/2024 Non-covered Recipient Entity
UCLA HEALTH SANTA MONICA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089689699
Principal investigator 1 Daiichi Sankyo Inc. $397,580.10 02/13/2024 Non-covered Recipient Entity
David Geffen School of Medicine at the University of California
2019-ESR-00133 No dispute reported 06/30/2026 1145040248
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,750.34 02/08/2024 Non-covered Recipient Entity
UCLA WESTLAKE VILLAGE PRIMARY AND SPECIALTY CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1089689995
Principal investigator 1 PFIZER INC. $24,357.00 02/07/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130933018
Recipient Novartis Pharmaceuticals Corporation $1,633.83 02/06/2024 Covered Recipient Physician CLEE011O12301C No dispute reported 06/30/2026 1089690037
Principal investigator 1 Daiichi Sankyo Inc. $6,534.00 02/02/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1145040590
Principal investigator 1 PFIZER INC. $578.00 02/01/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130929476
Principal investigator 1 PFIZER INC. $517.86 02/01/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130930386
Principal investigator 1 PFIZER INC. $7,678.00 01/18/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1130932638
Principal investigator 1 PFIZER INC. $10,220.00 01/11/2024 Covered Recipient Teaching Hospital
RESNICK NEUROPSYCHIATRIC HOSPITAL AT
A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER No dispute reported 06/30/2026 1130930063
Principal investigator 1 Daiichi Sankyo Inc. $20.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069862
Principal investigator 1 Daiichi Sankyo Inc. $63.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069864
Principal investigator 1 Daiichi Sankyo Inc. $204.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069866
Principal investigator 1 Daiichi Sankyo Inc. $378.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069868
Principal investigator 1 Daiichi Sankyo Inc. $1,650.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069870
Principal investigator 1 Daiichi Sankyo Inc. $2,488.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069872
Principal investigator 1 Daiichi Sankyo Inc. $9,429.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069874
Principal investigator 1 Daiichi Sankyo Inc. $11,712.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069876
Principal investigator 1 Daiichi Sankyo Inc. $14,553.00 01/03/2024 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 1086069878